Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
March 11 2022 - 6:34AM
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has
dosed the first participant in its Phase 1 study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynamics of
stabilized isoamyl nitrite (SIAN), a treatment being developed for
known or suspected acute cyanide poisoning. Under an existing
multi-year contract with the Biomedical Advanced Research and
Development Authority (BARDA), and in collaboration with the
Southwest Research Institute, Emergent is developing a single-use
intranasal spray intended for administration by first responders
and medical personnel following a cyanide incident.
“Emergent’s R&D efforts are grounded in our mission – to
protect and enhance life,” said Kelly Warfield, Ph.D., senior vice
president, research and development at Emergent BioSolutions. “We
are committed to advancing unique programs like SIAN, which
addresses the need for an easily administered first-line treatment
for cyanide poisoning. Intranasal SIAN is being developed for
potential use by both civilians and first responders and is part of
our portfolio of medical countermeasures focused on priority public
health threats identified by the U.S. government.”
This Phase 1, open label, single ascending dose clinical study
plans to enroll 70 healthy males or non-pregnant females between
the ages of 18 to 45. For more information on this study, visit
clinicaltrials.gov.
This study is funded by BARDA, a division of the Office of the
Assistant Secretary for Preparedness and Response within the U.S.
Department of Health and Human Services, under contract
HHSO100201700001C.
About Emergent BioSolutionsAt Emergent, our
mission is to protect and enhance life. For over 20 years, we’ve
been at work defending people from things we hope will never
happen—so we are prepared, just in case they ever do. We provide
solutions for complex and urgent public health threats through a
portfolio of vaccines and therapeutics that we develop and
manufacture for governments and consumers. We also offer a range of
integrated contract development and manufacturing services for
pharmaceutical and biotechnology customers. To learn more about how
we plan to protect or enhance 1 billion lives by 2030, visit our
website and follow us on LinkedIn, Twitter, and Instagram.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including statements
regarding our ability to fill the need for an easily administered
first-line treatment for cyanide poisoning and the safety and
immunogenicity of the product candidate are forward-looking
statements. The reader should realize that if underlying
assumptions prove inaccurate or unknown risks or uncertainties
materialize, actual results could differ materially from our
expectations. Readers are, therefore, cautioned not to place undue
reliance on any forward-looking statements, which speak only as of
the date of this press release.
There are a number of important factors that could cause the
company's actual results to differ materially from those indicated
by such forward-looking statements, including the success of the
planned development program; the timing of and ability to obtain
regulatory approvals for the product candidate; and our
commercialization, marketing and manufacturing capabilities. The
foregoing sets forth many, but not all, of the factors that could
cause actual results to differ from our expectations in any
forward-looking statement. Readers should consider this cautionary
statement, as well as the risk factors identified in our periodic
reports filed with the SEC, when evaluating our forward-looking
statements.
Investor Contact:Robert G.
BurrowsVice President, Investor
Relations240-631-3280burrowsr@ebsi.com
Media Contact:Matt HartwigSenior
Director, Media Relationsmediarelations@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Sep 2024 to Oct 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Oct 2023 to Oct 2024